Physician profile
Anna Tappel
NPI 1174083554
$7,930.36
in general payments reported to CMS, 2019-2025
22 companies · $6,086 in 2025
The $6,086 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $123 · 2024: $1,722 · 2025: $6,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,635 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,635.29 |
| Education | $295.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.77 | 2024-2025 | |
| Genzyme Corporation | $1,153.71 | 2023-2025 | |
| Pfizer INC. | $1,091.10 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $841.08 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $502.47 | 2024-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $459.34 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $412.17 | 2024-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $402.55 | 2024-2025 | Tremfya |
| Ucb, INC. | $330.98 | 2025 | Bimzelx |
| Lilly USA, LLC | $167.95 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $158.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.16 | 2024-2025 | Sotyktu |
| Dermavant Sciences, INC. | $149.19 | 2024 | Vtama |
| Leo Pharma INC. | $134.37 | 2025 | Anzupgo, Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.78 | 2025 | Cabtreo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $104.63 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $91.23 | 2025 | |
| Organogenesis INC. | $44.89 | 2025 | Via Matrix, Affinity |
| Nobelpharma America, LLC | $42.64 | 2025 | |
| Botanix Sb INC | $19.32 | 2025 | Sofdra |
| Amgen INC. | $13.72 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Tappel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.